Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01182493 · ClinicalTrials.gov registry record · NA
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
A NA study of Diabetes Mellitus, Type 2, sponsored by Medtronic Diabetes.
- Completed
- Registry status
- NA
- Development phase
- 331
- Enrollment target
- 20
- Study locations
NCT01182493: Completed NA study of Diabetes Mellitus, Type 2, sponsored by Medtronic Diabetes.
NCT01182493 is a NA study of Diabetes Mellitus, Type 2 that has completed, run by Medtronic Diabetes. The registered enrollment target is 331 participants, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01182493, a NA study of Diabetes Mellitus, Type 2, has completed, sponsored by Medtronic Diabetes.
- COMPLETED
- Registry status
- NA
- Development phase
- 331 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).
Primary Outcome
To evaluate change in glycemic control (HbA1c) after 6 months of insulin pump therapy in patients with type 2 DM, as compared to patients on MDI therapy over the same time period. Change in A1c = A1c at 6 month - A1c at baseline
Conditions Studied
Interventions
- DEVICE Insulin Pump (Medtronic Minimed Paradigm® VEO)
Study Locations (20)
Other
- City hopital Vienna-Hieting - Vienna
- CHU Côte de Nacre - Caen
- CHU - Ste Marguerite - Marseille
- Hopital Lapeyronie - Montpellier
- CHU de Nancy - Nancy
- CHU Strasbourg - Strasbourg
- CHU Toulouse Rangueil - Toulouse
- Fachklinik Bad Heilbrunn - Bad Heilbrunn
- Zentrum für Diabetes und Gefäßerkrankungen - Münster
Ontario
- LMC Endocrinology Centre - Oakville
- Canadian Centre for Research on Diabetes - Smiths Falls
- Toronto General Hsopital - Toronto
New York
- Albany Medical College - Albany
- SUNY Upstate Medical University - Syracuse
British Columbia
- Endocrinologist, 202-301 Columbia Street East - New Westminster
- 416-1033 Davie St - Vancouver
Georgia
- Atlanta Diabetes Associates - Atlanta
Alberta
- Clinical Professor Department of Medicine University of Calgary - Calgary
Newfoundland and Labrador
- Health Science Centre - St. John's
Quebec
- McGill University, McGill Nutrition and Food Science Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 331 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-08 |
| Phase | NA |
What the finished NCT01182493 record still lists
NCT01182493 is an interventional study that assigns participants to a tested intervention. The registered 331 participants enrollment target is mid-sized for trials with a published cap, below the 4,484-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Insulin Pump (Medtronic Minimed Paradigm® VEO) is the first listed.
NCT01182493 names 20 study sites across 8 states, led by Other, Ontario, New York.
Frequently Asked Questions
What is clinical trial NCT01182493 about?
NCT01182493 is a clinical study titled "OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy". The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily injections (MDI).
What is the current status of trial NCT01182493?
This trial is currently completed. It is a NA study. The enrollment target is 331 participants. The study started on 2010-12. Estimated completion is 2014-08.
What conditions does trial NCT01182493 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01182493?
The interventions under investigation include: Insulin Pump (Medtronic Minimed Paradigm® VEO) (DEVICE).
Who is sponsoring clinical trial NCT01182493?
This trial is sponsored by Medtronic Diabetes, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01182493 being conducted?
This trial has 20 study locations across Georgia, New York, Alberta, British Columbia, Newfoundland and Labrador. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01182493's enrollment target sits among peer trials
331 110th of 348 higher than 238 of 348 other Diabetes Mellitus, Type 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes
RECRUITING · NA
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Trial to Assess Continuous Glucose Monitoring in Asian Americans With Type 2 Diabetes
RECRUITING · NA
-
Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population
RECRUITING · NA
-
Phenotyping Genetic Risk for Type 2 Diabetes
RECRUITING · NA
-
Diabetes Learning in Virtual Environments Just in Time for Community Reentry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia